30 August 2017

NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT

Final agenda

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00.

Please note that this agenda is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Apologies – Part 1 only (open session)
  3. Any other business – Part 1 only (open session)
  4. Appraisal of regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
    • 4.1. Declarations of interest – Part 1 only (open session)
    • 4.2. Introduction by the Chair, Professor Gary McVeigh – Part 1 only (open session)
    • 4.3. Presentation by the Chair, Professor Gary McVeigh – Part 1 AND part 2 (open and closed session)
    • 4.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  5. Appraisal of vismodegib for treating basal cell carcinoma [ID1043]
    • 7.1. Declarations of interest – Part 1 only (open session)
    • 7.2. Introduction by the Vice Chair, Dr Lindsay Smith – Part 1 only (open session)
    • 7.3. Presentation by the Vice Chair, Dr Lindsay Smith – Part 1 AND part 2 (open and closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  6. Appraisal of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy [ID939]
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by the Chair, Professor Gary McVeigh – Part 1 only (open session)
    • 6.3. Presentation by the Chair, Professor Gary McVeigh – Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy [ID971]The company has requested to submit a new value proposition for nivolumab. Given the confidential nature of the information, this discussion will be held in a private (part 2) session.
    • 7.1. Declarations of interest – Part 2 only (closed session)
    • 7.2. Introduction by the Chair, Professor Gary McVeigh – Part 2 only (closed session)
    • 7.3. Presentation by the Chair, Professor Gary McVeigh – Part 2 only (closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Wednesday 27 September at NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT.

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Tuesday 15 August 2017Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Jon Littler.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 01 to 15 August 2017
Registration is closed.